Year: 2026
Type: article
Study design: Case Report
Abstract: Clozapine has been consistently found to be superior to other antipsychotic medications for the treatment of treatment-resistant schizophrenia, specifically in improving persistent psychotic symptoms. It is also associated with an improved quality of life as well as lower hospitalization rates, reduced suicidality, and premature mortality. Despite its lower risk of extrapyramidal side effects (EPS), clozapine is not considered first-line treatment for schizophrenia due to its array of adverse reactions. Rarely, clozapine may cause eosinophilia. We present a case of a 24-year-old Asian patient with treatment-resistant schizophrenia who developed eosinophilic cryptitis and crypt abscess after initiation of clozapine.
Source: Frontiers in Psychiatry
Institutions: National University Health System, Ministry of Health
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234459247
